Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection

The present study aimed to investigate the significance of the neutrophil to lymphocyte ratio (NLR) in peripheral blood of patients with small cell lung cancer (SCLC) when selecting a first-line treatment. A total of 73 patients with SCLC who had complete clinical data and sought treatment at Fujian...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology letters 2019-08, Vol.18 (2), p.1513-1520
Hauptverfasser:	Pan, Zhangchi, Zhang, Lu, Liu, Chen, Huang, Xiaobing, Shen, Songfei, Lin, Xiaoyan, Shi, Chunmei
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Antineoplastic agents Blood Cancer therapies Cancer treatment Carboplatin Care and treatment Chemotherapy Cisplatin Comparative analysis Dehydrogenases Development and progression Disease Health aspects Hematology Hospitals Lung cancer Lymphocytes Medical prognosis Medical records Medical research Medical schools Metastasis Mortality Neutrophils Patients Radiation (Physics) Radiation therapy Radiotherapy Research methodology Small cell lung cancer Studies Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present study aimed to investigate the significance of the neutrophil to lymphocyte ratio (NLR) in peripheral blood of patients with small cell lung cancer (SCLC) when selecting a first-line treatment. A total of 73 patients with SCLC who had complete clinical data and sought treatment at Fujian Medical University Union Hospital between January 2014 and May 2016 were included. Data were retrospectively analyzed, utilizing a receiver operating characteristic curve to determine the NLR cut-off value. Out of the 73 patients, 39 were classified as high-NLR (NLR ≥3.80) and 34 as low-NLR (NLR
ISSN:	1792-1074 1792-1082
DOI:	10.3892/ol.2019.10459